Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Dissociative

or Neuroleptic

Use the filters below to narrow your results.

Codeine (2)

None (22) · (multiple, generic dominant) (1) · Clozaril (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · DXM (1) · DXO (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Opana (1) · Orap (1) · Prolixin (1) · Saphris (1) · Spravato (1) · Stadol (1) · Stelazine (1) · Suboxone (1) · Talwin (1) · Thorazine (1) · Trilafon (1) · Vicodin (1)

Mu-opioid receptor agonist (4) · Phenothiazine D2 antagonist (4) · NMDA antagonist (3) · Potent mu-opioid receptor agonist (3) · NMDA antagonist; sigma receptor agonist (2)

Other values:

None (52) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (52) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (52) · 28 mg/device (each dose uses 2 devices) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (52) · 360 mg/day (1) · 84 mg per session (1)

None (52) · Intranasal (under direct medical supervision) (1) · PO (only formulation marketed in the US). (1)

None (52) · 30–60 min (PO) (1) · Within hours of first administration (1)

None (52) · 4–6 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (52) · 2.5–3 hours (1) · ~7-12 hours (1)

None (52) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (52) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (52) · Rx, Schedule III (US). REMS program required. (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 54 results in range #1 to #54.

2

2-FDCK

3

4

4-MeO-PCP

A

Asenapine

B

C

D

Droperidol

E

F

H

I

L

M

N

O

P

S

T

X

Xenon

Z

Ziprasidone

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"